These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Langley AK; Suffoletta TJ; Jennings HR Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515 [TBL] [Abstract][Full Text] [Related]
44. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Zhong J; Rao X; Rajagopalan S Atherosclerosis; 2013 Feb; 226(2):305-14. PubMed ID: 23083681 [TBL] [Abstract][Full Text] [Related]
45. Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion. McKillop AM; Stevenson CL; Moran BM; Abdel-Wahab YHA; Flatt PR Peptides; 2018 Feb; 100():165-172. PubMed ID: 29412816 [TBL] [Abstract][Full Text] [Related]
46. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. Chu XY; Bleasby K; Yabut J; Cai X; Chan GH; Hafey MJ; Xu S; Bergman AJ; Braun MP; Dean DC; Evers R J Pharmacol Exp Ther; 2007 May; 321(2):673-83. PubMed ID: 17314201 [TBL] [Abstract][Full Text] [Related]
47. Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet. Nakaya K; Kubota N; Takamoto I; Kubota T; Katsuyama H; Sato H; Tokuyama K; Hashimoto S; Goto M; Jomori T; Ueki K; Kadowaki T Metabolism; 2013 Jul; 62(7):939-51. PubMed ID: 23790528 [TBL] [Abstract][Full Text] [Related]
48. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Kendall DM; Kim D; Maggs D Diabetes Technol Ther; 2006 Jun; 8(3):385-96. PubMed ID: 16800760 [TBL] [Abstract][Full Text] [Related]
49. Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia. Herzberg-Schäfer S; Heni M; Stefan N; Häring HU; Fritsche A Diabetes Obes Metab; 2012 Oct; 14 Suppl 3():85-90. PubMed ID: 22928568 [TBL] [Abstract][Full Text] [Related]
50. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518 [TBL] [Abstract][Full Text] [Related]
51. New incretin hormonal therapies in humans relevant to diabetic cats. Reusch CE; Padrutt I Vet Clin North Am Small Anim Pract; 2013 Mar; 43(2):417-33. PubMed ID: 23522180 [TBL] [Abstract][Full Text] [Related]
52. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182 [TBL] [Abstract][Full Text] [Related]
53. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes. Singh AK; Jatwa R; Purohit A; Ram H J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157 [TBL] [Abstract][Full Text] [Related]
54. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Thornberry NA; Gallwitz B Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065 [TBL] [Abstract][Full Text] [Related]
55. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases. Xie W; Song X; Liu Z Vascul Pharmacol; 2018 Oct; 109():17-26. PubMed ID: 29879463 [TBL] [Abstract][Full Text] [Related]